Initial Statement of Beneficial Ownership (3)

FORM 3	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES	OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response... 0.5
	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person ^*

Garella Rahul

2. Date of Event Requiring Statement (MM/DD/YYYY) 8/1/2019

3. Issuer Name and Ticker or Trading Symbol

Endo International plc [ENDP]

(Last) (First) (Middle)

C/O ENDO INTERNATIONAL PLC, FIRST FL, MINERVA HOUSE, SIMMONSCOURT RD

4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director _____ 10% Owner
___ X ___ Officer (give title below) _____ Other (specify below)
EVP, Intl Pharmaceuticals /

(Street)

BALLSBRIDGE, DUBLIN, L2

(City) (State) (Zip)

5. If Amendment, Date Original Filed (MM/DD/YYYY)

6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares	24116	D
2015 Stock Incentive Plan Restricted Stock Units (RSU) ⁽¹⁾	236	D
2015 Stock Incentive Plan Restricted Stock Units (RSU) ⁽²⁾	353	D
2015 Stock Incentive Plan Restricted Stock Units (RSU) ⁽³⁾	3538	D
2015 Stock Incentive Plan Restricted Stock Units (RSU) ⁽⁴⁾	16047	D
2015 Stock Incentive Plan Restricted Stock Units (RSU) ⁽⁵⁾	39700	D
2015 Stock Incentive Plan Restricted Stock Units (RSU) ⁽⁶⁾	26902	D

*Table II - Derivative Securities Beneficially Owned ( e.g.* , puts, calls, warrants, options, convertible securities)**
1. Title of Derivate Security (Instr. 4)	2. Date Exercisable and Expiration Date (MM/DD/YYYY)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivate Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security		6. Nature of Indirect Beneficial Ownership (Instr. 5)
2015 Stock Incentive Plan Options (NQ) ⁽⁷⁾	⁽⁷⁾	10/1/2025	Ordinary Shares	3422.0	$70.02	D
2015 Stock Incentive Plan Options (NQ) ⁽⁸⁾	⁽⁸⁾	2/23/2026	Ordinary Shares	4764.0	$50.22	D
2015 Stock Incentive Plan Options (NQ) ⁽⁹⁾	⁽⁹⁾	2/21/2027	Ordinary Shares	23810.0	$13.19	D
2015 Stock Incentive Plan Options (NQ) ⁽¹⁰⁾	⁽¹⁰⁾	8/10/2027	Ordinary Shares	54707.0	$7.55	D

Explanation of Responses:
(1)	On October 1, 2015, 946 RSUs were granted to Mr. Garella with one-fourth vesting, and thus expiring, on each of the first four grant date anniversaries. As of August 1, 2019, 710 RSUs were vested and released. The amount reported in Table I represents the unvested portion as of that date.
(2)	On February 23, 2016, 1,412 RSUs were granted to Mr. Garella with one-fourth vesting, and thus expiring, on each of the first four grant date anniversaries. As of August 1, 2019, 1,059 RSUs were vested and released. The amount reported in Table I represents the unvested portion as of that date.
(3)	On February 21, 2017, 10,614 RSUs were granted to Mr. Garella with one-third vesting, and thus expiring, on each of the first three grant date anniversaries. As of August 1, 2019, 7,076 RSUs were vested and released. The amount reported in Table I represents the unvested portion as of that date.
(4)	On August 10, 2017, 24,071 RSUs were granted to Mr. Garella with one-third vesting, and thus expiring, on each of the first three grant date anniversaries. As of August 1, 2019, 8,024 RSUs were vested and released. The amount reported in Table I represents the unvested portion as of that date.
(5)	On April 2, 2018, 59,551 RSUs were granted to Mr. Garella with one-third vesting, and thus expiring, on each of the first three grant date anniversaries. As of August 1, 2019, 19,851 RSUs were vested and released. The amount reported in Table I represents the unvested portion as of that date.
(6)	On March 29, 2019, 26,902 RSUs were granted to Mr. Garella with one-third vesting, and thus expiring, on each of the first three grant date anniversaries.
(7)	On October 1, 2015, 3,422 non-qualified stock options were granted to Mr. Garella with one-fourth vesting on each of the first four grant date anniversaries. As of August 1, 2019, 2,567 non-qualified stock options were vested and released.
(8)	On February 23, 2016, 4,764 non-qualified stock options were granted to Mr. Garella with one-fourth vesting on each of the first four grant date anniversaries. As of August 1, 2019, 3,573 non-qualified stock options were vested and released.
(9)	On February 21, 2017, 23,810 non-qualified stock options were granted to Mr. Garella with one-fourth vesting on each of the first four grant date anniversaries. As of August 1, 2019, 11,906 non-qualified stock options were vested and released.
(10)	On August 10, 2017, 54,707 non-qualified stock options were granted to Mr. Garella with one-third vesting on each of the first three grant date anniversaries. As of August 1, 2019, 18,236 non-qualified stock options were vested and released.

Remarks:
On July 30, 2019, Endo International plc appointed Mr. Garella as EVP, International Pharmaceuticals. These securities represent the amounts owned by Mr. Garella as of August 1, 2019, the date of effectiveness of his appointment.

Reporting Owners
Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
Garella Rahul C/O ENDO INTERNATIONAL PLC FIRST FL, MINERVA HOUSE, SIMMONSCOURT RD BALLSBRIDGE, DUBLIN, L2			EVP, Intl Pharmaceuticals

Signatures
/s/ Yoon Ah Oh, by power of attorney		8/9/2019
^** Signature of Reporting Person		Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
*	If the form is filed by more than one reporting person, see Instruction 5(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note:	File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.